Luitel Prajjwol, Poudel Bibek, Upadhyay Devansh, Paudel Sujan, Tiwari Nishan, Gajurel Bikram Prasad, Karn Ragesh, Rajbhandari Reema, Shrestha Aashish, Gautam Niraj, Ojha Rajeev
Tribhuvan University Institute of Medicine, Kathmandu, Nepal.
Department of Neurology, Tribhuvan University Institute of Medicine, Kathmandu, Nepal.
SAGE Open Med Case Rep. 2022 May 20;10:2050313X221100876. doi: 10.1177/2050313X221100876. eCollection 2022.
ChAdOx1 nCoV-19 is an effective and well-tolerated coronavirus disease 2019 vaccine. However, rare cases of serious adverse events have been reported with it. We report a patient who did not have active or prior coronavirus disease 2019 infection, who developed Guillain-Barré syndrome 7 days following the first dose of ChAdOx1 nCoV-19 vaccination. He was treated with intravenous immunoglobulin, with stabilization of the disease. Proper monitoring and prompt reporting of such cases are required to ensure the safety of the vaccine.
ChAdOx1 nCoV-19是一种有效且耐受性良好的2019冠状病毒病疫苗。然而,已有关于其罕见严重不良事件的报道。我们报告了一名未曾感染过现症或既往2019冠状病毒病的患者,在接种第一剂ChAdOx1 nCoV-19疫苗后7天出现了吉兰-巴雷综合征。他接受了静脉注射免疫球蛋白治疗,病情得以稳定。需要对此类病例进行适当监测并及时报告,以确保疫苗的安全性。